Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS in Subjects with Lupus Nephritis Biotech Investing
LevelJump Engages Independent Trading Group, Inc. for Market Making Services Medical Device Investing
U.S. Food and Drug Administration Approves Opdivo® as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy Biotech Investing
SHRMF DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Champignon Brands Inc. - SHRMF Psychedelics Investing
Wellteq Management Webcast on May 25, 2021 Chief Medical Officer - Dr. George Gellert Biotech Investing
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock Psychedelics Investing
Lexaria's Newest DehydraTECH 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever Biotech Investing
Lexaria's Newest DehydraTECH 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever Biotech Investing
Braxia Scientific Introduces the Braxia Institute, Turning Research to Clinical Action; Over 200 Physicians and Health Care Providers to Attend Braxia's Symposium on Rapid Acting Anti-Depressants Psychedelics Investing
Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors Biotech Investing
Merck Announces Positive Topline Results from PNEU-DIRECTION and PNEU-PLAN Phase 3 Pediatric Studies for V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine Pharmaceutical Investing
